Five Year Summary
2013
2014
2015
2016
2017
Dose sales (units)
7,299
8,561
10,252
11,931
12,578
Sales revenue ($'000)
96,774
129,363
176,088
232,492
234,282
Profit / (loss) before income tax ($'000)
24,507
31,110
52,768
69,998
(40,954)
Net profit / (loss) ($'000)
18,270
23,868
40,345
53,582
(26,257)
R&D investment ($'000)
6,615
7,981
8,641
10,835
11,865
Clinical investment ($'000) *
15,872
22,168
20,724
20,631
24,852
Capital investment ($'000)
3,685
6,187
1,692
1,718
1,239
Total assets at 30 June ($'000)
117,766
148,710
201,476
261,717
194,122
Total equity at 30 June ($'000)
87,684
107,583
144,636
193,504
149,467
Net tangible assets at 30 June ($'000)
59,762
60,219
76,609
110,683
140,941
Earnings (loss) per share (cents)
32.8
42.5
71.4
93.7
(45.5)
Dividends per share (cents)
12
14
20
30
30

* Excludes SIRFLOX amortisation expense

 

Charts



Now leaving sirtex.com

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.

Continue

×

You are now leaving your current sirtex.com region

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.

Continue

×